首页> 外文OA文献 >405 – Efficacy and Safety Results 48 Weeks After Switching from Tenofovir Disoproxil Fumarate (TDF) to Tenofovir Alafenamide (TAF) Vs Continued Tdf Treatment in Virologically-Suppressed Patients with Chronic Hepatitis B (CHB)

【2h】

405 – Efficacy and Safety Results 48 Weeks After Switching from Tenofovir Disoproxil Fumarate (TDF) to Tenofovir Alafenamide (TAF) Vs Continued Tdf Treatment in Virologically-Suppressed Patients with Chronic Hepatitis B (CHB)

机译：405 - 从替诺福韦解毒型（TDF）切换到替诺福韦（TDF）到替芬罗霉素（TAF）对病毒学抑制患者的慢性乙型肝炎（CHB）的持续治疗，疗效和安全结果48周

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Pietro Lampertico; Maria Buti; Scott Fung; Sang Hoon Ahn; Wan-Long Chuang; Won Young Tak; Alnoor Ramji; Chi-Yi Chen; Edward Tam; Ho Bae; Xiaoli Ma; John F. Flaherty; Anuj Gaggar; Audrey H. Lau; Becket Feierbach; George Wu; Vithika Suri; Mani Subramanian; Huy N. Trinh; Seung-Kew Yoon; Kosh Agarwal; Young-Suk Lim; Henry L. Chan;
展开▼
作者单位

展开▼
年度 2019
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Improved Bone and Renal Safety at 1 Year after Switching from Tenofovir Disoproxil Fumarate (TDF) to Tenofovir Alafenamide (TAF): Results from 2 Phase 3 Studies in HBeAg-positive and HBeAg-negative Patients with Chronic Hepatitis B (CHB) [J] . Pan Calvin Q., Brunetto Maurizia R., Hui Aric Josun, Hepatology: Official Journal of the American Association for the Study of Liver Diseases . 2017,第Suppla1期

机译：从替诺福韦毒性富马酸核（TDF）转向替诺福韦·阿拉芬酰胺（TAF）后1年改善骨骼和肾脏安全性：结果来自2阶段3研究的HBEAG阳性和HBEAG阴性慢性乙型肝炎（CHB）的研究结果
2. Efficacy and Safety of Tenofovir Alafenamide (TAF) at 96 Weeks in Chronic HBV (CHB) Patients with Risk Factors for Use of Tenofovir Disoproxil Fumarate (TDF) [J] . Buti Maria, Stepanova Tatjana, Celen Mustafa K., Hepatology: Official Journal of the American Association for the Study of Liver Diseases . 2017,第Suppla1期

机译：Tenofovir Alafenainide（TAF）在慢性HBV（CHB）患者使用胞多虫患者危险因素的患者96周（TDF）的患者（TDF）患者的疗效和安全性
3. Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in treatment-experienced, virologically-suppressed adults living with HIV-1 [J] . Eron Joseph J., Orkin Chloe, Cunningham Douglas, Antiviral Research . 2019,第期

机译：第9周的疗效和安全结果3阶段，随机祖母绿试验评估从增强蛋白酶抑制剂的切换加上Emtricitabine / Tenofovir Disoproxil富马酸莫霉素治疗达伦韦/钴/ Emtricitabine / Tenofovir Alafenaine的单片体方案（D / C / F / TAF）在治疗经验丰富的病毒学 - 被抑制的成年人与HIV-1一起生活
4. Efficacy and Safety of Didanosine (ddI) and Tenofovir (TDF) Combination as NRTI Backbone of Highly Active Antiretrovirai Treatment (HAART). (24 wk Preliminary Results from Recover Study). [C] . M.J. Galindo, J. Lopez Aldeguer, M. Salavert International AIDS Conference . 2004

机译：脱蛋白（DDI）和替诺福韦（TDF）组合作为高活性抗逆转录（HAART）的NRTI骨架的疗效和安全性。（恢复研究中的24条WK初步结果）。
5. Week 48 Results of EMERALD: A Phase 3 Randomized Non-inferiority Study Evaluating the Efficacy and Safety of Switching from Boosted-protease Inhibitors (bPI) Plus Emtricitabine (FTC)/Tenofovir Disoproxil Fumarate (TDF) Regimens to the Once Daily (QD) Single-tablet Regimen (STR) of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) in Virologically Suppressed HIV-1-infected Adults [O] . Chloe Orkin, Jean-Michel Molina, Joel Gallant, 2017

机译：EMERALD的第48周结果：第3阶段的非劣效性研究评估了从加强蛋白酶抑制剂（bPI）加恩曲他滨（FTC）/替诺福韦富马酸替诺福韦酯（TDF）转换为每日一次（QD）的功效和安全性）在病毒学上被抑制感染了HIV-1的成年人中Darunavir / Cobicistat / Emtricitabine / Tenofovir Alafenamide（D / C / F / TAF）的单片治疗方案（STR）
6. IDDF2020-ABS-0060 Impact of prior tenofovir disoproxil fumarate (TDF) treatment duration on tenofovir alafenamide (TAF) safety profile in virally suppressed chronic HBV patients switched from TDF to TAF [O] . Henry Lik Yuen Chan, Pietro Lampertico, Sang Hoon Ahn, 2020

机译：IDDF2020-ABS-ABS-0060对Tenofovir umarovir umarate（TDF）治疗持续时间在替诺福韦anafenamide（TAF）的慢性HBV患者在从TDF转换为TAF

405 – Efficacy and Safety Results 48 Weeks After Switching from Tenofovir Disoproxil Fumarate (TDF) to Tenofovir Alafenamide (TAF) Vs Continued Tdf Treatment in Virologically-Suppressed Patients with Chronic Hepatitis B (CHB)

著录项

引文网络

相似文献

相关主题

期刊订阅